Recommending a science- and risk-based plan for ensuring products meet potency standards, the US Food and Drug Administration (FDA) has issued final guidance for manufacturers of cellular and gene therapy (CGT) products.
The final guidance document for Potency Assurance for Cellular and Gene Therapy Products lays out the FDA’s recommendations